Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma

Endometrial Serous carcinoma (ESC) has similar molecular characteristics to high-grade serous ovarian carcinoma (HGSOC) and basal cell-like breast cancer, such as similar Chromosomal instability, somatic copy number variation profiles and somatic mutations. The clinical treatment of ESC also refers to the treatment model of HGSOC. The PARP inhibitor niraparib used in this study, which was approved by FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemot

Trial Details

NCT ID
NCT04716686
Phase
PHASE2
Sponsor
Shandong University
Status
RECRUITING
Cancer Type
Uterine Serous Carcinoma Uterine Cancer
Interventions
  • Niraparib
Locations (sample)
  • Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

  • Women aged 18 or above
  • Histological confirmation of serous endometrial cancer or other types of endometrial cancer
  • FIGO stage III-IV
  • ESC Patients have received at least 6 cycles of first-line platinum containing chemotherapy after surgery and achieved CR, PR or SD; ESC patients h…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Serous Carcinoma Uterine Cancer Trials on Trialify →